Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Nephrol Dial Transplant
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.
Zayed MG. et al, (2024), JAMA Ophthalmol
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60
Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland
PREISS D. et al, (2023), BMJ Quality and Safety
Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.
Seekircher L. et al, (2023), Eur Heart J Open, 3
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017.
Thalmann I. et al, (2022), Heart
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
BAIGENT C. et al, (2022), The Lancet
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
Kohli-Lynch CN. et al, (2022), Circulation